Actively Recruiting
A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis
Led by Mayo Clinic · Updated on 2026-01-08
30
Participants Needed
1
Research Sites
195 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to investigate the impact of the probiotic Lactobacillus rhamnosus (LGG) on proton pump inhibitor (PPI)-induced changes to the microbes that live in the gastrointestinal tract and are passed out in the stool. PPI medicines reduce stomach acid and are commonly used to treat acid reflux disease.
CONDITIONS
Official Title
A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals on an unrestricted regular diet with no dietary restrictions such as vegan, low FODMAP, gluten free, dairy-free, keto, or intermittent fasting
- Healthy subjects with no current or chronic gastrointestinal symptoms as assessed by a 16-item questionnaire
You will not qualify if you...
- Prior surgery altering the esophagus, stomach, or intestines, except appendectomy
- Chronic daily use of medications that affect gastrointestinal secretion or motor function
- Presence of gastrointestinal motility-affecting systemic diseases or untreated psychiatric disease
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mayo Clinic Arizona
Scottsdale, Arizona, United States, 85259
Actively Recruiting
Research Team
A
Alexandria Ramirez
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here